Sihuan Pharmaceutical Holdings GroupSHPHF 52 Net Current Asset Value is $0.01 as of Dec. 2025, which is 100% below its 10-year median of 4.70. GuruFocus rates SHPHF with a GF Score™ of 52/100 and a GF Value™ of $0.17 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 613 Drug Manufacturers companies, Sihuan Pharmaceutical Holdings Group ranks worse than 63.13% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
The historical rank and industry rank for Sihuan Pharmaceutical Holdings Group's Net Current Asset Value or its related term are showing as below:
SHPHF'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.38 Med: 4.7 Max: 11.09
Current: 8.09
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Sihuan Pharmaceutical Holdings Group was 11.09. The lowest was 2.38. And the median was 4.70.
SHPHF's Price-to-Net-Current-Asset-Value is ranked worse than 63.13% of 613
companies
in the Drug Manufacturers industry
Industry Median: 5.71
vs SHPHF: 8.09
Sihuan Pharmaceutical Holdings Group (OTCPK:SHPHF) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Sihuan Pharmaceutical Holdings Group Net Current Asset Value Related Terms
Sihuan Pharmaceutical Holdings Group Net Current Asset Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sihuan Pharmaceutical Holdings Group Net Current Asset Value Chart
SHPHF vs ZTS, UTHR: Net Current Asset Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sihuan Pharmaceutical Holdings Group's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sihuan Pharmaceutical Holdings Group Price-to-Net-Current-Asset-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sihuan Pharmaceutical Holdings Group's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Sihuan Pharmaceutical Holdings Group's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $0.01 mean?
Sihuan Pharmaceutical Holdings Group (SHPHF) has a Net Current Asset Value of $0.01 as of Dec. 2025. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Sihuan Pharmaceutical Holdings Group and its competitors. This is 100% below median its historical median of 4.70. Over the past decade, Sihuan Pharmaceutical Holdings Group's Net Current Asset Value has ranged from 2.38 to 11.09. According to the industry distribution chart, Sihuan Pharmaceutical Holdings Group ranks #387 out of 613 companies in the Drug Manufacturers industry, placing it in the top 63.1%.
Is Sihuan Pharmaceutical Holdings Group's Net Current Asset Value too high?
Sihuan Pharmaceutical Holdings Group's current Net Current Asset Value of $0.01 is 100% below median its 10-year median of 4.70. Over the past 10 years, this metric has ranged from a low of 2.38 to a high of 11.09. The Drug Manufacturers industry median Net Current Asset Value is 5.71. Sihuan Pharmaceutical Holdings Group's value of $0.01 is 99.8% below this industry median. Based on the distribution chart, Sihuan Pharmaceutical Holdings Group ranks #387 out of 613 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Sihuan Pharmaceutical Holdings Group has a GF Score™ of 52/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sihuan Pharmaceutical Holdings Group's Net Current Asset Value compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sihuan Pharmaceutical Holdings Group ranks #387 out of 613 companies for Net Current Asset Value. This places Sihuan Pharmaceutical Holdings Group in the lower half of its industry. The industry median Net Current Asset Value is 5.71. Sihuan Pharmaceutical Holdings Group's value of $0.01 is 99.8% below this benchmark. Historically, Sihuan Pharmaceutical Holdings Group's own Net Current Asset Value has ranged from 2.38 to 11.09 over the past decade. While the company's 10-year median is 4.70 vs. the industry median of 5.71, Sihuan Pharmaceutical Holdings Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Drug Manufacturers company?
The median Net Current Asset Value among Drug Manufacturers companies is 5.71, based on 613 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sihuan Pharmaceutical Holdings Group's current Net Current Asset Value of $0.01 is 99.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Sihuan Pharmaceutical Holdings Group and its competitors. For the Drug Manufacturers industry, the median Net Current Asset Value is 5.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sihuan Pharmaceutical Holdings Group's current Net Current Asset Value is $0.01, which is 100% below median its own 10-year median of 4.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sihuan Pharmaceutical Holdings Group stock overvalued right now?
Based on GuruFocus' analysis, Sihuan Pharmaceutical Holdings Group (SHPHF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.17, compared to a current price of $0.13 — trading 23.7% below its estimated fair value. The current Net Current Asset Value is $0.01, which is 100% below median its 10-year median of 4.70 and 99.8% below the Drug Manufacturers industry median of 5.71. Sihuan Pharmaceutical Holdings Group's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Sihuan Pharmaceutical Holdings Group (SHPHF), the current Net Current Asset Value is $0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sihuan Pharmaceutical Holdings Group (SHPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Sihuan Pharmaceutical Holdings Group stock appears to be undervalued.
The current stock price of $0.13 is trading 23.7% below its estimated GF Value™ of $0.17.
GuruFocus considers Sihuan Pharmaceutical Holdings Group to be Modestly Undervalued.
Key valuation signals for SHPHF:
Net Current Asset Value: $0.01 (100% below median its 10-year median of 4.70)
GF Value™: $0.17 vs. price of $0.13 (23.7% below fair value)
Industry Position: 99.8% below the Drug Manufacturers median (#387 of 613)
No single metric tells the full story. See the SHPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sihuan Pharmaceutical Holdings Group Business Description
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Respiratory, Neurology, and others. The group has three reportable segments: the medical aesthetic products segment, including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others; the innovative medicine and other medicine segment; and the generic medicine segment, which generates key revenue. Geographically, the company generates a majority of its revenue from Mainland China and the rest from the United States.
52GF Score
Get the complete analysis for SHPHF
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHPHF has been successfully added to your 
